Hints and tips:
Related Special Reports
...Fruergaard Jørgensen said that a tablet product from the acquisition last year of a Canadian biotech, Inversago, could be a scalable weight-loss pill and alternative to the popular GLP-1-based drugs....
...the sale if a buyer is found....
...It booked a 6 per cent loss in 2022, a year the company described in its most recent annual report as “among the most challenging in recent memory, from both a geopolitical and economic perspective”....
...“The whole system has a just-in-time principle and any rupture in that causes a downstream shortage,” says Rob Moss, a hospital pharmacy consultant in Utrecht, the Netherlands....
...Novo Nordisk has struck a €1bn deal for a German biotech developing ribonucleic acid-based therapies to treat heart disease, as the Danish group invests the windfall from its best-selling diabetes and weight...
...Novo Nordisk has struck a €1bn deal for Cardior Pharmaceuticals, a German biotech company developing RNA-based therapies to treat heart disease, as it seeks to build expertise in diseases beyond diabetes...
...The tribunal ruled that the largest company in the FTSE 100 discriminated against James Muir — a leading scientist who had been developing the pharmaceutical company’s drug, Truqap — on the basis of a disability...
...The company will increase its footprint at a Cambridge biomedical site and build a vaccine manufacturing site in Speke in Liverpool....
...The funds have been awarded by the British Business Bank, a state-owned lender.The money is part of the government’s ambition to encourage pension schemes to invest more in unlisted UK companies....
...Canadian biotech Fusion is a specialist in radioconjugates, a drug type that involves delivering a radioactive isotope directly to cancer cells through precise targeting, reducing the damaging side effects...
...Patients require a single treatment....
...Patients with terminal breast cancer in England will be denied access to a new treatment that has already been approved in Scotland, after a public health body said the drug did not provide value for money...
...It has also made a bet on the new generation of cancer drugs known as antibody-drug conjugates, such as Enhertu....
...A new study by Novo Nordisk has shown that its blockbuster drug Ozempic cut the risk of death, disease progression and cardiovascular issues by 24 per cent for patients with type 2 diabetes and chronic kidney...
...Its best-selling Tagrisso drug showed a “statistically significant and highly clinically meaningful” improvement in preventing the progression of a version of the most common form of the disease, the company...
...In a lot of places in the world, it’s not a safe thing to do.”...
...Novo Nordisk shares have hit a new record after the Danish drugmaker revealed early stage results for a new weight loss pill that offers better results than its blockbuster Wegovy....
...“Unfortunately, it’s a trend that we’ve seen for a number of companies....
...Revenue was slightly ahead of analysts’ expectations, with oncology drugs making up more than a third of sales....
...McKernan did not set a timeline for reaching the half a million prospective clinical trial cohort, which she said was a personal view and not an official target....
...steatohepatitis (MASH), compared with a placebo, after a 48-week, mid-stage trial....
...Moderna swung to a loss in 2023 as the Covid-19 vaccine maker suffered a sharp reversal in fortunes due to lower uptake of its jab....
...It has a list price of £1,455 per vial, although it is available to the NHS at an undisclosed discount....
..., will fill Zepbound injector pens at its Cincinnati plant, which will have a total capacity of 200mn doses a year by 2025....
...However, its failure to produce a Covid-19 jab ahead of rivals with less expertise in vaccines dealt it a reputational blow....
International Edition